Opus Genetics (IRD) Consolidated Net Income (2010 - 2026)

Opus Genetics (IRD) has reported Consolidated Net Income for 17 consecutive years, with -$65.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Consolidated Net Income fell 699.79% year-over-year to -$65.5 million; the TTM figure through Mar 2026 stood at -$96.5 million (down 64.65% YoY), while the FY2025 annual figure was -$39.2 million, up 31.9% from the prior year.
• Consolidated Net Income slipped to -$65.5 million in Q1 2026 per IRD's latest filing, from -$6.1 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $33.9 million in Q4 2022 and bottomed at -$65.5 million in Q1 2026.
• Historically, Consolidated Net Income has averaged -$9.1 million across 5 years, with a median of -$6.6 million in 2022.
• Annual changes were most pronounced in 2022 — Consolidated Net Income surged 637.64% — and 2026, when it plunged 699.79%.
• Opus Genetics' Consolidated Net Income stood at $33.9 million in 2022, then slumped by 114.13% to -$4.8 million in 2023, then slumped by 632.74% to -$35.1 million in 2024, then jumped by 82.61% to -$6.1 million in 2025, then plunged by 972.76% to -$65.5 million in 2026.
• Business Quant data shows IRD's Consolidated Net Income at -$65.5 million in Q1 2026, -$6.1 million in Q4 2025, and -$17.5 million in Q3 2025.